Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Serono Austria GMBH
EVIDENCE-Umstellungsstudie (22 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 9: Patientencharakteristik Abb. 10: Studienendpunkte Abb. 11: Umstellung Aktuelles Bild - Abb. 12: Patienten Abb. 13: Schubrate Abb. 14: Umstellung Avonex - Rebif Abb. 15: MRT-Ergebnisse  - Rebif Zum letzten Bild
Abbildung 12: Patienten
This slide presents the proportion of patients who remain relapse-free during the post-T interval for both groups and is compared with the original 24 week data from EVIDENCE for the same patients who continue in the post-Transition time. Slide shows that the difference seen at 0-24 is likely due to Rx since the outcome within each group is considerably different based on dose but between doses is very different in weeks 0 to 24 but very similar once all patients on Rebif 44/44 means Rebif from start and 30/44 is Avonex to Rebif switch group.
 
Patienten
Vorheriges Bild Nächstes Bild   


Abbildung 12: Patienten
This slide presents the proportion of patients who remain relapse-free during the post-T interval for both groups and is compared with the original 24 week data from EVIDENCE for the same patients who continue in the post-Transition time. Slide shows that the difference seen at 0-24 is likely due to Rx since the outcome within each group is considerably different based on dose but between doses is very different in weeks 0 to 24 but very similar once all patients on Rebif 44/44 means Rebif from start and 30/44 is Avonex to Rebif switch group.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung